Resonant Down 70%… Could CorMedix Inc. (CRMD) Be Next?Guest Post
Last February we warned about Resonant and since then the stock has fallen over 70%. We believe Coremedix has many of the same attributes that alarmed us about RESN. We believe CRMD is wildly overvalued, is poised for a big drop and suggest that investors avoid or consider shorting CRMD.
CorMedix has a market capitalization of $400 million, its stock is up 370% year to . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.